Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Titel:
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Auteur:
Chappell, Keith J. Mordant, Francesca L. Amarilla, Alberto A. Modhiran, Naphak Liang, Benjamin Li, Zheyi Wijesundara, Danushka K. Lackenby, Julia A. Griffin, Paul Bennet, Jillian K. Hensen, Luca Zhang, Wuji Nguyen, Thi H.O. Tran, Mai H. Tapley, Peter Barnes, James Reading, Patrick C. Kedzierska, Katherine Ranasinghe, Charani Subbarao, Kanta Watterson, Daniel Young, Paul R. Munro, Trent P.